Hansa Biopharma

Virtual Investor Event

Autoimmune Deep Dive
Guillain-Barré Syndrome 

Join Hansa Biopharma for an investor event featuring KOLs David R. Cornblath, MD (Johns Hopkins University), and Simon Rinaldi, MRCP(Neuro), PhD (University of Oxford), discussing unmet need and current treatment landscape for Guillain-Barré syndrome (GBS).

June 16, 14:00 CEST/8:00 AM ET

Register and attend
CareersPipelineCollaboration RareInnovation SVGOMG The best SVG optimizer and minifier Open SVG Paste markup Demo Contribute SVGOMG provides you several options to clean and compress your SVG files. Clean up, remove, merge, minify. Upload or copy the source of your SVG to get started! 947 bytes → 267 bytes 28.19% Finance peopleAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes

Hansa Medical arranges information meetings in Malmö and Stockholm

1 Jun 2011, 15:00
Regulatory information
Hansa Medical carries out a new share issue in order to reach crucial and very interesting development milestones, and arranges information meetings in Stockholm and Malmö, Sweden. The company is presented by CEO Emanuel Björne.


Information meetings

Stockholm
Date: Thursday June 9, 2011
Time: 18.00 – 20.00
Venue: Avanza Bank, Regeringsgatan 103, Stockholm
RSVP: At the latest on June 9, Hansa Medical at phone 046-16 56 70 or via e-mail [email protected] or notification through the website of Avanza Bank.

Malmö
Date: Monday June 13, 2011
Time: 18.00 – 20.00
Venue: Comfort Hotel Malmö at Carlsgatan 10 C (by Centralstationen).
RSVP: At the latest on June 9, Hansa Medical at phone 046-16 56 70 or via e-mail [email protected] or notification through the website of Avanza Bank.

Please notify your interest as soon as possible since the number of seats is limited.

Schedule for the new share issue
16 May 2011, Last trading day for the share with right to participate in the share issue
19 May 2011, Record day
23 May 2011, Publication of the prospectus
26 May – 14 June 2011, Subscription period
26 May – 9 June2011, Subscription rights trading
17 June 2011, Outcome published

The new share issue prospectus and a more general information brochure (in Swedish only) is available at www.hansamedical.com

Avanza Bank is the financial advisor and Fredersen Advokatbyrå is the legal advisor of Hansa Medical.

Files

For further information, please contact:
Hansa Medical AB
Emanuel Björne, CEO
Mobile: +46 707 17 54 77
E-mail: [email protected]

Hansa Medical is a biopharmaceutical development company focused on inflammation. The company develops innovative biopharmaceuticals and diagnostics in partnership with major companies with market presence as well as under full Hansa Medical management. At present, three primary product candidates are in development; IdeS, anti-alpha-11 and HMD-301. Novel research projects and product candidates are generated through academic collaborations and in-house development. Hansa Medical is publicly traded at NASDAQ OMX First North under ticker symbol HMED. Remium AB is Certified Adviser to Hansa Medical.